Sign In / Join

close

Clinical Trials

Our Clinical Trials articles highlight top clinical trials, their results, and how patients can participate in them.

Headlines All Categories Treatment Advances Navigating Your Health Core Education Patient Stories HealthTree Research Conferences Clinical Trials HealthTree Programs HealthTree Press

Recent Articles

New Clinical Trial Treatment Causes Myelofibrosis Cell Death

February 07, 2025

What is navtemadlin, and how does this treatment in clinical trials help stop myelofibrosis cells and improve cancer-related symptoms?

Ruxolitinib and Anemia in Myelofibrosis: Real-World Survival Outcomes in the United States

February 03, 2025

Learn how anemia impacts survival in myelofibrosis patients treated with ruxolitinib. Discover key findings from the phase 3b JUMP study.

Advancing Myelofibrosis Treatment: The Promise of the SENTRY Trial

December 02, 2024

The SENTRY trial represents a large step forward for unmet needs of MF patients by treating them with selinexor.

RVU120: A New Treatment in Clinical Trials for AML, MDS, and Myelofibrosis

October 22, 2024

What is RVU120, a new medicine in clinical trials, and how may it help reduce signs/symptoms of AML, MDS, and myelofibrosis?

What are Clinical Trials, and How May They Help Me?

September 30, 2024

Learn about clinical trials to open the door to accessing innovative cancer treatments.

The MANIFEST 2 Trial: Pelabresib and Ruxolitinib

May 22, 2024

One of the largest trials in myelofibrosis is testing pelabresib with ruxolitinib and will be sharing new updates soon! Stay tuned!

Clinical Trials

Recent Articles

New Clinical Trial Treatment Causes Myelofibrosis Cell Death

Ruxolitinib and Anemia in Myelofibrosis: Real-World Survival Outcomes in the United States

Advancing Myelofibrosis Treatment: The Promise of the SENTRY Trial

RVU120: A New Treatment in Clinical Trials for AML, MDS, and Myelofibrosis

What are Clinical Trials, and How May They Help Me?

The MANIFEST 2 Trial: Pelabresib and Ruxolitinib

Trending Articles

Investigating CK0804 as an Add-On Therapy to Ruxolitinib for Improved Myelofibrosis Management

New Treatments for Improving Low Blood Counts in Myelofibrosis Patients

New Clinical Trial Treatment Causes Myelofibrosis Cell Death

Ruxolitinib and Anemia in Myelofibrosis: Real-World Survival Outcomes in the United States

How Effective are Stem Cell Transplants for Senior Patients with Myelofibrosis?

Education

Community

Cure Hub

Get Involved

About us

Need Help?

Legal Info

Follow Us

Clinical Trials

Recent Articles

New Clinical Trial Treatment Causes Myelofibrosis Cell Death

Ruxolitinib and Anemia in Myelofibrosis: Real-World Survival Outcomes in the United States

Advancing Myelofibrosis Treatment: The Promise of the SENTRY Trial

RVU120: A New Treatment in Clinical Trials for AML, MDS, and Myelofibrosis

What are Clinical Trials, and How May They Help Me?

The MANIFEST 2 Trial: Pelabresib and Ruxolitinib

Trending Articles

Investigating CK0804 as an Add-On Therapy to Ruxolitinib for Improved Myelofibrosis Management

New Treatments for Improving Low Blood Counts in Myelofibrosis Patients

New Clinical Trial Treatment Causes Myelofibrosis Cell Death

Ruxolitinib and Anemia in Myelofibrosis: Real-World Survival Outcomes in the United States

How Effective are Stem Cell Transplants for Senior Patients with Myelofibrosis?

Get the Latest Multiple Myeloma Updates, Delivered to You.

Education

Community

Cure Hub

Get Involved

About us

Need Help?

Legal Info

Follow Us